Geneva, Switzerland, 19 June 2017 – 7:30am CEST : – GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that the first patient has been treated in its Australian Phase 2a study of GNbAC1 in type 1 diabetes. This is GNbAC1’s second indication after multiple sclerosis, for which an international Phase 2b study is ongoing in 260 patients.

Further information can be found at :